Prenatal treatment of Down syndrome: A reality?

Current Opinion in Obstetrics and Gynecology

Volumn 26, Issue 2, 2014, Pages 92-103

  Guedj, Fayçal ^a   Bianchi, Diana W ^a   Delabar, Jean Maurice ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Clinical trials; Down syndrome; mouse models; prenatal treatment; trisomy 21

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; APIGENIN; CHOLINE; EPIGALLOCATECHIN GALLATE; FLUOXETINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN DYRK1A; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; CATECHIN; DYRK KINASE; NEUROPROTECTIVE AGENT; PROTEIN SERINE THREONINE KINASE;

BRAIN DEVELOPMENT; CLINICAL TRIAL (TOPIC); COGNITION; DOWN SYNDROME; ELECTROPHYSIOLOGY; ENVIRONMENTAL ENRICHMENT; EXERCISE; HUMAN; LEARNING; MEMORY; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PERINATAL PERIOD; PRENATAL CARE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NEURAL STEM CELL; NEWBORN; PREGNANCY; PROCEDURES; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TRANSGENIC MOUSE; TRENDS;

ANIMALS; ANIMALS, NEWBORN; APIGENIN; CATECHIN; CHOLINE; DISEASE MODELS, ANIMAL; DOWN SYNDROME; FEMALE; FLUOXETINE; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEURAL STEM CELLS; NEUROGENESIS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PREGNANCY; PRENATAL CARE; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RECEPTORS, GABA; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

EID: 84896396949     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000056     Document Type: Review

References (95)

1. Lockstone HE, Harris LW, Swatton JE, et al. Gene expression profiling in the adult Down syndrome brain. Genomics 2007; 90:647-660.
2. Ait Yahya-Graison E, Aubert J, Dauphinot L, et al. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am J Hum Genet 2007; 81:475-491.
3. Duchon A, Raveau M, Chevalier C, et al. Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. Mamm Genome 2011; 22:674-684.
4. Reinholdt LG, Ding Y, Gilbert GJ, et al. Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mamm Genome 2011; 22:685-691.
5. Fox WM. Reflex-ontogeny and behavioural development of the mouse. Anim Behav 1965; 13:234-241.
6. Takahashi A, Yap JJ, Bohager DZ, et al. Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl) 2009; 204:61-71.
7. Armstrong CM, DeVito LM, Cleland TA. One-trial associative odor learning in neonatal mice. Chem Senses 2006; 31:343-349.
8. Baxter LL, Moran TH, Richtsmeier JT, et al. Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum Mol Genet 2000; 9:195-202.
9. Chen Y, Dyakin VV, Branch CA, et al. In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model. Neurobiol Aging 2009; 30:1453-1465.
10. Chakrabarti L, Galdzicki Z, Haydar TF. Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J Neurosci 2007; 27:11483-11495.
11. Siarey RJ, Carlson EJ, Epstein CJ, et al. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 1999; 38:1917-1920.
12. Siarey RJ, Villar AJ, Epstein CJ, Galdzicki Z. Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome. Neuropharmacology 2005; 49:122-128.
13. Belichenko PV, Kleschevnikov AM, Salehi A, et al. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotypephenotype relationships. J Comp Neurol 2007; 504:329-345.
14. Saran NG, Pletcher MT, Natale JE, et al. Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. Hum Mol Genet 2003; 12:2013-2019.
15. Amano K, Sago H, Uchikawa C, et al. Dosage-dependent over-expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome. Hum Mol Genet 2004; 13:1333-1340.
16. Laffaire J, Rivals I, Dauphinot L, et al. Gene expression signature of cerebellar hypoplasia in a mouse model of Down syndrome during postnatal development. BMC Genomics 2009; 10:138; 2164-10-138.
17. Kern DS, Maclean KN, Jiang H, et al. Neural stem cells reduce hippocampal tau and reelin accumulation in aged Ts65Dn Down syndrome mice. Cell Transplant 2011; 20:371-379.
18. Rachubinski AL, Crowley SK, Sladek JR Jr, et al. Effects of neonatal neural progenitor cell implantation on adult neuroanatomy and cognition in the Ts65Dn model of Down syndrome. PLoS One 2012; 7:e36082.
19. Rachubinski AL, Maclean KN, Evans JR, Bjugstad KB. Modulating cognitive deficits and tau accumulation in a mouse model of aging Down syndrome through neonatal implantation of neural progenitor cells. Exp Gerontol 2012; 47:723-733.
20. Martinez-Cue C, Baamonde C, Lumbreras M, et al. Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome. Behav Brain Res 2002; 134:185-200.
21. Dierssen M, Benavides-Piccione R, Martinez-Cue C, et al. Alterations of neocortical pyramidal cell phenotype in the Ts65Dn mouse model of Down syndrome: effects of environmental enrichment. Cereb Cortex 2003; 13:758-764.
22. Martinez-Cue C, Rueda N, Garcia E, et al. Behavioral, cognitive and biochemical responses to different environmental conditions in male Ts65Dn mice, a model of Down syndrome. Behav Brain Res 2005; 163:174-185.
23. Baamonde C, Martinez-Cue C, Florez J, Dierssen M. G-protein-associated signal transduction processes are restored after postweaning environmental enrichment in Ts65Dn, a Down syndrome mouse model. Dev Neurosci 2011; 33:442-450.
24. Chakrabarti L, Scafidi J, Gallo V, Haydar TF. Environmental enrichment rescues postnatal neurogenesis defect in the male and female Ts65Dn mouse model of Down syndrome. Dev Neurosci 2011; 33:428-441.
25. Llorens-Martin MV, Rueda N, Tejeda GS, et al. Effects of voluntary physical exercise on adult hippocampal neurogenesis and behavior of Ts65Dn mice, a model of Down syndrome. Neuroscience 2010; 171:1228-1240.
26. Kida E, Rabe A, Walus M, et al. Long-term running alleviates some behavioral and molecular abnormalities in Down syndrome mouse model Ts65Dn. Exp Neurol 2013; 240:178-189.
27. Ortiz-Abalia J, Sahun I, Altafaj X, et al. Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome. Am J Hum Genet 2008; 83:479-488.
28. Altafaj X, Martin ED, Ortiz-Abalia J, et al. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 2013; 52:117-127.
29. Guedj F, Sebrie C, Rivals I, et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One 2009; 4:e4606.
30. De la Torre R, De Sola S, PonsM, et al. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol Nutr Food Res 2013.
31. Souchet B, Guedj F, Sahul I, et al. Excitation/inhibition balance and learning are disrupted by Dyrk1a gene dosage modification and rescued by EGCG treatment. Neurobiol Dis 2013. (Under review).
32. Shichiri M, Yoshida Y, Ishida N, et al. alpha-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. Free Radic Biol Med 2011; 50:1801-1811.
33. Lockrow J, Prakasam A, Huang P, et al. Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol 2009; 216:278-289.
34. Fernandez F, Morishita W, Zuniga E, et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 2007; 10:411-413.
35. Rueda N, Florez J, Martinez-Cue C. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci Lett 2008; 433:22-27.
36. Colas D, Chuluun B, Warrier D, et al. Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome. Br J Pharmacol 2013; 169:963-973.
37. Braudeau J, Dauphinot L, Duchon A, et al. Chronic treatment with a promnesiant GABA-A alpha5-Selective inverse agonist increases immediate early genes expression during memory processing in mice and rectifies their expression levels in a Down syndrome mouse model. Adv Pharmacol Sci 2011; 2011:153218.
38. Braudeau J, Delatour B, Duchon A, et al. Specific targeting of the GABA-A receptor alpha5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J Psychopharmacol 2011; 25:1030-1042.
39. Vidal V, Garcia S, Martinez P, et al. Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome. Neuroscience 2012; 220:158-168.
40. Kleschevnikov AM, Belichenko PV, Faizi M, et al. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci 2012; 32:9217-9227.
41. Martinez-Cue C, Martinez P, Rueda N, et al. Reducing GABAA alpha5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of Down syndrome. J Neurosci 2013; 33:3953-3966.
42. Costa AC, Scott-McKean JJ, Stasko MR. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008; 33:1624-1632.
43. Rueda N, Llorens-Martin M, Florez J, et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis 2010; 21:277-290.
44. Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res 2011; 221:610-622.
45. Siddiqui A, Lacroix T, Stasko MR, et al. Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801. Genes Brain Behav 2008; 7:810-820.
46. Nguyen CD, Costa AC, Cios KJ, Gardiner KJ. Machine learning methods predict locomotor response to MK-801 in mouse models of Down syndrome. J Neurogenet 2011; 25:40-51.
47. Clark S, Schwalbe J, Stasko MR, et al. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp Neurol 2006; 200:256-261.
48. Heinen M, Hettich MM, Ryan DP, et al. Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. Neural Plast 2012; 2012:467251.
49. Bianchi P, Ciani E, Guidi S, et al. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci 2010; 30:8769-8779.
50. Guidi S, Stagni F, Bianchi P, et al. Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome. Brain Pathol 2013; 23:129-143.
51. Stagni F, Magistretti J, Guidi S, et al. Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of Down syndrome. PLoS One 2013; 8:e61689.
52. Contestabile A, Greco B, Ghezzi D, et al. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J Clin Invest 2013; 123:348-361.
53. Moran TH, Capone GT, Knipp S, et al. The effects of piracetam on cognitive performance in a mouse model of Down's syndrome. Physiol Behav 2002; 77:403-409.
54. de Souza FM, Busquet N, Blatner M, et al. Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome. Sci Rep 2011; 1:137.
55. Moon J, Chen M, Gandhy SU, et al. Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome. Behav Neurosci 2010; 124:346-361.
56. Rueda N, Florez J, Martinez-Cue C. Effects of chronic administration of SGS- 111 during adulthood and during the pre and postnatal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome. Behav Brain Res 2008; 188:355-367.
57. Dang V, Medina B, Das D, et al. Formoterol, a long-acting beta2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome. Biol Psychiatry 2013; 75:179-188.
58. Salehi A, Faizi M, Colas D, et al. Restoration of norepinephrine- modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med 2009; 1:7ra17.
59. Faizi M, Bader PL, Tun C, et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis 2011; 43:397-413.
60. Corrales A, Vidal R, Garcia S, et al. Chronic melatonin treatment rescues electrophysiological and neuromorphological deficits in a mouse model of Down syndrome. J Pineal Res 2013; 56:51-61.
61. Corrales A, Martinez P, Garcia S, et al. Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome. J Pineal Res 2013; 54:346-358.
62. Netzer WJ, Powell C, Nong Y, et al. Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS One 2010; 5:e10943.
63. Hunter CL, Bachman D, Granholm AC. Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann Neurol 2004; 56:675-688.
64. Gutierrez-Castellanos N, Winkelman BH, Tolosa-Rodriguez L, et al. Size does not always matter: Ts65Dn Down syndrome mice show cerebellum-dependent motor learning deficits that cannot be rescued by postnatal SAG treatment. J Neurosci 2013; 33:15408-15413.
65. Das I, Park JM, Shin JH, et al. Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model. Sci Transl Med 2013; 5:201ra120.
66. Incerti M, Toso L, Vink J, et al. Prevention of learning deficit in a Down syndrome model. Obstet Gynecol 2011; 117 (2 Pt 1):354-361.
67. Toso L, Cameroni I, Roberson R, et al. Prevention of developmental delays in a Down syndrome mouse model. Obstet Gynecol 2008; 112:1242-1251.
68. Vink J, Incerti M, Toso L, et al. Prenatal NAP-SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-Daspartic acid and gamma-aminobutyric acid receptors. Am J Obstet Gynecol 2009; 200:524e1-524e4.
69. Granholm AC, Ford KA, Hyde LA, et al. Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome. Physiol Behav 2002; 77:371-385.
70. Granholm AC, Sanders L, Seo H, et al. Estrogen alters amyloid precursor protein as well as dendritic and cholinergic markers in a mouse model of Down syndrome. Hippocampus 2003; 13:905-914.
71. Slonim DK, Koide K, Johnson KL, et al. Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses. Proc Natl Acad Sci U S A 2009; 106:9425-9429.
72. Pagano G, Castello G. Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv Exp Med Biol 2012; 724:291-299.
73. Incerti M, Horowitz K, Roberson R, et al. Prenatal treatment prevents learning deficit in Down syndrome model. PLoS One 2012; 7:e50724.
74. Bumbalo TS, Morelewicz HV, Berens DL. Treatment of Down's syndrome with the 'U' series of drugs. JAMA 1964; 187:361.
75. Simonsson H. Therapy with 5-hydroxytryptophan of Down's disease. Nord Med 1969; 81:952-954.
76. Weise P, Koch R, Shaw KN, Rosenfeld MJ. The use of 5-HTP in the treatment of Down's syndrome. Pediatrics 1974; 54:165-168.
77. Lobaugh NJ, Karaskov V, Rombough V, et al. Piracetam therapy does not enhance cognitive functioning in children with Down syndrome. Arch Pediatr Adolesc Med 2001; 155:442-448.
78. Heller JH, Spiridigliozzi GA, Crissman BG, et al. Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study. J Child Adolesc Psychopharmacol 2006; 16:755-765.
79. Prasher VP, Sachdeva N, Adams C, Haque MS. Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study. Int J Geriatr Psychiatry 2013; 28:219-220.
80. Spiridigliozzi GA, Heller JH, Crissman BG, et al. Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. Am J Med Genet A 2007; 143A:1408-1413.
81. Kishnani PS, Heller JH, Spiridigliozzi GA, et al. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. Am J Med Genet A 2010; 152A:3028-3035.
82. Blehaut H, Mircher C, Ravel A, et al. Effect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status. PLoS One 2010; 5:e8394.
83. Ellis JM, Tan HK, Gilbert RE, et al. Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial. BMJ 2008; 336:594-597.
84. Lott IT, Doran E, Nguyen VQ, et al. Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A 2011; 155A:1939-1948.
85. Myrelid A, Bergman S, Elfvik Stromberg M, et al. Late effects of early growth hormone treatment in Down syndrome. Acta Paediatr 2010; 99:763-769.
86. Boada R, Hutaff-Lee C, Schrader A, et al. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry 2012; 2:e141.
87. Hanney M, Prasher V, Williams N, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, doubleblind, placebo-controlled trial. Lancet 2012; 379:528-536.
88. Florez J, del Arco C, Gonzalez A, et al. Autoradiographic studies of neurotransmitter receptors in the brain of newborn infants with Down syndrome. Am J Med Genet Suppl 1990; 7:301-305.
89. Kish SJ, Distefano LM, Dozic S, et al. 3H]vesamicol binding in human brain cholinergic deficiency disorders. Neurosci Lett 1990; 117:347-352.
90. Guedj F, Bianchi DW. Noninvasive prenatal testing creates an opportunity for antenatal treatment of Down syndrome. Prenat Diagn 2013; 33:614-618.
91. Beni-Adani L, Gozes I, Cohen Y, et al. A peptide derived from activitydependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther 2001; 296:57-63.
92. Incerti M, Vink J, Roberson R, et al. Reversal of alcohol-induced learning deficits in the young adult in a model of fetal alcohol syndrome. Obstet Gynecol 2010; 115 (2 Pt 1):350-356.
93. Slonim DK, Koide K, Johnson KL, et al. Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses. Proc natl Acad Sci U S A 2009; 106:9425-9429.
94. Guedj F, Hines D, Foley JC, et al. Translating the transcriptome to develop antenatal treatments for fetuses with Down syndrome. Reprod Sci 2013; 20 (Suppl):64A.
95. Guidi S, Stagni F, Bianchi P, et al. Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. Brain 2013. Dec 12 (Epub ahead of print).